thalidomide has been researched along with Alveolitis, Fibrosing in 11 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, the potential effects of thalidomide (Thal) on bleomycin (BLM)-induced pulmonary fibrosis were investigated." | 7.85 | Antiinflammation and Antioxidant Effects of Thalidomide on Pulmonary Fibrosis in Mice and Human Lung Fibroblasts. ( Chen, M; Dong, X; Fan, Q; Li, M; Li, X; Wei, W, 2017) |
| "Silicosis is the most prevalent occupational disease in China." | 5.72 | Thalidomide Alleviates Pulmonary Fibrosis Induced by Silica in Mice by Inhibiting ER Stress and the TLR4-NF-κB Pathway. ( Cai, W; Jin, F; Li, T; Li, Y; Liu, H; Liu, W; Wang, X; Xu, H; Yang, F; Yang, X, 2022) |
| "Thalidomide (Thal) has been used in the treatment of multiple myeloma through the inhibitory effect on IL-6-dependent cell growth and angiogenesis." | 5.34 | Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. ( Hisamori, S; Kadokawa, Y; Kubo, H; Mishima, M; Nakano, T; Tabata, C; Tabata, R; Takahashi, M, 2007) |
| "To evaluate the immune regulatory and anti-fibrosis function of thalidomide (Thal) in systemic sclerosis (SSc), we investigated the effects of Thal on: (a) Th17 and Treg cell production; (b) related factors expression; and (c) transforming growth factor (TGF)-β1/Smad3 pathway, using a mouse model of SSc." | 3.96 | Effects of thalidomide on Th17, Treg cells and TGF-β1/Smad3 pathway in a mouse model of systemic sclerosis. ( Lei, L; Li, X; Lu, Y; Tao, Z; Wen, J; Zhao, C; Zheng, L, 2020) |
| "Pomalidomide, previously used to treat multiple myeloma, has been reported to cause acute pulmonary toxicity that improves with drug discontinuation." | 3.88 | Pulmonary toxicity associated with pomalidomide. ( Blanc, PD; Brown, JK; Callahan, EC; Elicker, B; Gajic, S; Ley, B, 2018) |
| "In this study, the potential effects of thalidomide (Thal) on bleomycin (BLM)-induced pulmonary fibrosis were investigated." | 3.85 | Antiinflammation and Antioxidant Effects of Thalidomide on Pulmonary Fibrosis in Mice and Human Lung Fibroblasts. ( Chen, M; Dong, X; Fan, Q; Li, M; Li, X; Wei, W, 2017) |
| "Silicosis is the most prevalent occupational disease in China." | 1.72 | Thalidomide Alleviates Pulmonary Fibrosis Induced by Silica in Mice by Inhibiting ER Stress and the TLR4-NF-κB Pathway. ( Cai, W; Jin, F; Li, T; Li, Y; Liu, H; Liu, W; Wang, X; Xu, H; Yang, F; Yang, X, 2022) |
| "Thalidomide (THD) has a therapeutic effect on fibrotic and inflammatory disorders." | 1.48 | Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-β/Smad3 signaling pathway in an Nrf2-dependent manner. ( Bian, C; Chen, J; Qin, WJ; Wang, YY; Zhang, CY; Zhao, R; Zhe, H; Zhu, YZ; Zou, GL, 2018) |
| "Thalidomide (Thal) has been used in the treatment of multiple myeloma through the inhibitory effect on IL-6-dependent cell growth and angiogenesis." | 1.34 | Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. ( Hisamori, S; Kadokawa, Y; Kubo, H; Mishima, M; Nakano, T; Tabata, C; Tabata, R; Takahashi, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 1 |
| Cai, W | 1 |
| Jin, F | 1 |
| Wang, X | 1 |
| Liu, W | 1 |
| Li, T | 1 |
| Yang, X | 1 |
| Liu, H | 1 |
| Xu, H | 1 |
| Yang, F | 1 |
| Finato, AC | 1 |
| Almeida, DF | 1 |
| Dos Santos, AR | 1 |
| Nascimento, DC | 1 |
| Cavalcante, RS | 1 |
| Mendes, RP | 1 |
| Soares, CT | 1 |
| Paniago, AMM | 1 |
| Venturini, J | 1 |
| Lu, Y | 1 |
| Zhao, C | 1 |
| Lei, L | 1 |
| Tao, Z | 1 |
| Zheng, L | 1 |
| Wen, J | 1 |
| Li, X | 2 |
| Zheng, F | 1 |
| Zhu, J | 1 |
| Zhang, W | 1 |
| Fu, Y | 1 |
| Lin, Z | 1 |
| Dong, X | 1 |
| Li, M | 1 |
| Chen, M | 1 |
| Fan, Q | 1 |
| Wei, W | 1 |
| Bian, C | 1 |
| Qin, WJ | 1 |
| Zhang, CY | 1 |
| Zou, GL | 1 |
| Zhu, YZ | 1 |
| Chen, J | 1 |
| Zhao, R | 1 |
| Wang, YY | 1 |
| Zhe, H | 1 |
| Gajic, S | 1 |
| Callahan, EC | 1 |
| Brown, JK | 1 |
| Elicker, B | 1 |
| Ley, B | 1 |
| Blanc, PD | 1 |
| Horton, MR | 1 |
| Danoff, SK | 1 |
| Lechtzin, N | 1 |
| Choe, JY | 1 |
| Jung, HJ | 1 |
| Park, KY | 1 |
| Kum, YS | 1 |
| Song, GG | 1 |
| Hyun, DS | 1 |
| Park, SH | 1 |
| Kim, SK | 1 |
| Subbian, S | 1 |
| Tsenova, L | 1 |
| O'Brien, P | 1 |
| Yang, G | 1 |
| Koo, MS | 1 |
| Peixoto, B | 1 |
| Fallows, D | 1 |
| Zeldis, JB | 1 |
| Muller, G | 1 |
| Kaplan, G | 1 |
| Tabata, C | 1 |
| Tabata, R | 1 |
| Kadokawa, Y | 1 |
| Hisamori, S | 1 |
| Takahashi, M | 1 |
| Mishima, M | 1 |
| Nakano, T | 1 |
| Kubo, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Pomalidomide in the Treatment of Refractory Cough in Patients With Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study[NCT01135199] | Phase 2 | 0 participants (Actual) | Interventional | 2010-04-30 | Withdrawn (stopped due to FDA did not accept sponsor's animal toxicology data to support proposed dosing.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for thalidomide and Alveolitis, Fibrosing
| Article | Year |
|---|---|
Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis.
Topics: Antitussive Agents; Cough; Humans; Prospective Studies; Pulmonary Fibrosis; Thalidomide | 2008 |
10 other studies available for thalidomide and Alveolitis, Fibrosing
| Article | Year |
|---|---|
Thalidomide Alleviates Pulmonary Fibrosis Induced by Silica in Mice by Inhibiting ER Stress and the TLR4-NF-κB Pathway.
Topics: Animals; Mice; NF-kappa B; Pulmonary Fibrosis; Silicon Dioxide; Silicosis; Thalidomide; Toll-Like Re | 2022 |
Evaluation of antifibrotic and antifungal combined therapies in experimental pulmonary paracoccidioidomycosis.
Topics: Animals; Antifungal Agents; Azithromycin; Cytokines; Disease Models, Animal; Drug Therapy, Combinati | 2020 |
Effects of thalidomide on Th17, Treg cells and TGF-β1/Smad3 pathway in a mouse model of systemic sclerosis.
Topics: Animals; Cytokines; Disease Models, Animal; Female; Fibrosis; Hydroxyproline; Immunosuppressive Agen | 2020 |
Thal protects against paraquat-induced lung injury through a microRNA-141/HDAC6/IκBα-NF-κB axis in rat and cell models.
Topics: Animals; Apoptosis; Cell Line; Disease Models, Animal; Female; Histone Deacetylase 6; Inflammation M | 2021 |
Antiinflammation and Antioxidant Effects of Thalidomide on Pulmonary Fibrosis in Mice and Human Lung Fibroblasts.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cells, Cultured; Fibroblasts; Humans; Inflammation; | 2017 |
Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-β/Smad3 signaling pathway in an Nrf2-dependent manner.
Topics: A549 Cells; Animals; Cell Line, Tumor; Epithelial Cells; Female; Gene Expression Regulation; Humans; | 2018 |
Pulmonary toxicity associated with pomalidomide.
Topics: Antineoplastic Agents; Humans; Lung; Male; Middle Aged; Multiple Myeloma; Pneumonia; Pulmonary Fibro | 2018 |
Anti-fibrotic effect of thalidomide through inhibiting TGF-beta-induced ERK1/2 pathways in bleomycin-induced lung fibrosis in mice.
Topics: Angiogenesis Inhibitors; Animals; Bleomycin; Cells, Cultured; Disease Models, Animal; Dose-Response | 2010 |
Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology.
Topics: Animals; Antitubercular Agents; Blotting, Western; Colony-Forming Units Assay; Cyclic Nucleotide Pho | 2011 |
Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice.
Topics: Animals; Bleomycin; Cell Differentiation; Cell Line; Cell Line, Transformed; Collagen Type I; Collag | 2007 |